[latest discovery and innovation] a spray can effectively prevent novel coronavirus infection. On June 6, Chongqing Medical University announced that the research led by Professor Huang ailing / Professor Jin aishun's team had found antibody 58g6 with strong neutralizing activity against Omicron covid-19 variant, and proved the effectiveness of nasal administration in blocking the replication of Omicron variant. Relevant papers were recently published in the journal signal transduction and targeted therapy. "Every time novel coronavirus mutates, a batch of neutralizing antibodies developed by many scientific research institutions around the world will fail. In particular, Omicron has more mutation sites, and few effective neutralizing antibodies have survived. Fortunately, the 58g6 neutralizing antibody we screened still maintains effective neutralizing activity." Jin aishun introduced that the antibody 58g6 jointly identified by them and the team of the Wuhan Institute of Virology, when used alone, can show strong neutralization ability against Pseudoviruses of alpha, beta, gamma, Delta, Omicron and other concerned mutants of novel coronavirus, showing that it has broad-spectrum neutralization activity. The researchers tested the neutralization effect of this antibody in hamsters by intranasal administration. The results showed that the nasal administration of 58g6 at a very low concentration (2 mg / kg) could effectively prevent hamsters from contracting live Omicron virus. The ba. 2 sub mutant strain ba. 2.12.1 found in New York, USA, and the ba. 4 and ba 5 and others are spreading rapidly. Among the three mutant strains, the key mutation l452 of delta also exists - it is this mutation site that gives delta the advantage of transmission. It was found that 58g6 antibody was effective against ba 1 + l452r is also very effective. According to Huang Ailong, the novel coronavirus neutralizing antibody nasal spray drug (for prevention) developed by the university has completed the preparation of all preclinical research materials and has recently been submitted to the new drug review center of the State Food and drug administration. (outlook new era)